Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $27.38.

A number of research firms have issued reports on KURA. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Jefferies Financial Group reduced their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Scotiabank reduced their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,255 shares of company stock valued at $100,739 over the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC lifted its stake in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. raised its holdings in shares of Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after acquiring an additional 23,113 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Kura Oncology by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after acquiring an additional 14,106 shares during the period.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $8.03 on Friday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The firm has a 50-day simple moving average of $9.02 and a 200 day simple moving average of $15.58. The company has a market cap of $624.41 million, a PE ratio of -3.40 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the business earned ($0.50) EPS. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.